Clinical Trials Directory

Trials / Unknown

UnknownNCT02035904

Levobupivacaine Prolonged Wound Infusion for Postoperative Pain Relief After Breast Surgery

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia · Academic / Other
Sex
Female
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to evaluate efficacy and safety of long term (14 days) wound infusion with levobupivacaine in patients with breast cancer undergoing mastectomy with immediate breast reconstruction: this is a double blind, randomized, parallel group study. The study moves from the concept that nociceptive stimulus last further than 48 hours after surgical intervention: long term analgesia is necessary to provide a real benefit to the patient and provide central sensitization. Intralesional catheter is placed at the end of surgery. In the first 24 postoperative hours we provide continuous wound infusion with levobupivacaine 0,25% 5ml/h with morphine Patient Controlled Analgesia (PCA) when NRS \>4. From the second postoperative day morphine PCA is removed and patients are randomized to receive levobupivacaine 0,25% or saline, released with 5 ml boluses and lock-out of 2 hours, with rescue analgesia with tramadol 37,5 mg + acetaminophen 325 mg oral fix combination (Patrol). Intralesional catheter is taken off 14 days after surgical intervention or after 36 hours of non-use. Pain evaluation (NRS at rest and movement) and oral rescue doses consumption are performed; pain physicians also care about any catheter-related or drug-related side effect, registering number of total boluses. Patients are provided with a home diary for pain scores to be filled and brought back when surgical visit is performed. A phone interview at 1 and 3 month is performed to investigate pain chronicization. Surgical evaluation is provided, also to establish any catheter-related infective or healing complication. Physiatric evaluation before the intervention and 1 and 3 months is provided to ensure rehabilitation process. A validated questionnaire (short form 36/ SF-36) must be filled by all patients, to understand differences in return to a normal quality of life and to social activities between the two groups.

Conditions

Interventions

TypeNameDescription
DRUGLevobupivacaine PCIA (Patient Controlled Intrawound Analgesia)patient controlled infusion from the 2nd day after surgery
DRUGsalinepatient controlled infusion from the 2nd day after surgery
DRUGLevobupivacaine continuous infusionContinuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
DEVICEintrawound infusion catheterplaced by surgeon at the end surgery in all patients
DRUGmorphinePCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
DRUGPatroltramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)

Timeline

Start date
2013-01-01
Primary completion
2017-09-01
Completion
2017-12-01
First posted
2014-01-14
Last updated
2017-03-03

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02035904. Inclusion in this directory is not an endorsement.